Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of NZ-C1909 for Lumbar Interbody Fusion
jRCT2011260004Phase 3Recruiting
- Sponsor
- Nippon Zoki Pharmaceutical
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of NZ-C1909 in degenerative lumbar disc disease (DDD) (2 arms), sponsored by Nippon Zoki Pharmaceutical. Primary endpoint: Bone fusion at week 104 (CT). Started May 2026; status: recruiting.
02
Drugs
NZ-C1909
03
Conditions
degenerative lumbar disc disease (DDD)
Beyond the preview
Go deeper on jRCT2011260004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260004.